Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

Core Viewpoint - Apogee Therapeutics Inc. (APGE) has seen a 9.9% increase in share price over the past four weeks, closing at $40.98, with analysts projecting a potential upside of 129.1% based on a mean price target of $93.88 [1][12]. Price Targets - The average price target consists of eight estimates ranging from a low of $78 to a high of $116, with a standard deviation of $11.05, indicating a potential increase of 90.3% to 183.1% from the current price [2][9]. - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates - Analysts are optimistic about APGE's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11][12]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 9.2%, with three estimates moving higher and no negative revisions [12]. Analyst Consensus - APGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside in the near term [13].